FIGS Releases Fourth Quarter and Full Year 2024 Financial Results

In This Article:

2024 Results Exceed Expectations with Net Revenues Growth of 1.8% YoY, Net Income Margin of 0.5%, and Adjusted EBITDA Margin of 9.3%

Increases Share Repurchase Authorization by $50 Million

SANTA MONICA, Calif., February 27, 2025--(BUSINESS WIRE)--FIGS, Inc. (NYSE: FIGS) (the "Company"), the global leading healthcare apparel brand dedicated to improving the lives of healthcare professionals, today released its fourth quarter and full year 2024 financial results and published a financial highlights presentation on its investor relations website at ir.wearfigs.com/financials/quarterly-results/.

Fourth Quarter 2024 Financial Highlights

  • Net revenues were $151.8 million, an increase of 4.8% year over year, primarily due to an increase in orders from existing customers.

    • Scrubwear net revenues were $114.7 million, an increase of 2.4% year over year.

    • Non-scrubwear net revenues were $37.2 million, an increase of 12.8% year over year.

    • U.S. net revenues were $127.5 million, a decrease of 0.5% year over year.

    • International net revenues were $24.3 million, an increase of 45.2% year over year.

  • Gross margin was 67.3%, a decrease of 20 basis points year over year, primarily due to product mix shifts, partially offset by a benefit from duty drawback claims.

  • Operating expenses were $93.3 million, an increase of 11.6% year over year. As a percentage of net revenues, operating expenses increased to 61.4% from 57.7% in the same period last year, primarily due to higher operational costs at our new fulfillment center, higher shipping costs, and lapping the outsized favorable impact in Q4 2023 as a result of the inception of our duty reclassification method last year.

  • Net income and net income, as adjusted(1) were $1.9 million (or $0.01 in diluted earnings per share), a decrease of $8.1 million year over year as compared to net income and net income, as adjusted(1) in the same period last year.

  • Net income margin(2) was 1.2%, as compared to 6.9% in the same period last year.

  • Adjusted EBITDA(1) was $21.1 million, a decrease of $5.5 million year over year.

  • Adjusted EBITDA margin(1)(2) was 13.9%, as compared to 18.4% in the same period last year.

"We finished the year with solid momentum, as our fourth quarter results exceeded our expectations and were powered by an impactful flow of product newness driving repeat frequency," said Trina Spear, Chief Executive Officer and Co-Founder. "While overall 2024 financial results were mixed, we look forward to seeing our industry and Company normalize coming out of the COVID overhang that impacted us over the past couple years. We intend to accelerate our strategic pillars to drive long-term sustainable and profitable growth through product innovation, deep connection with our community, and meeting our healthcare professionals where they are, both online and offline. We remain confident in our brand positioning, our strategic focus, and the long-term structural strength of the healthcare industry."


Waiting for permission
Allow microphone access to enable voice search

Try again.